Eledon Pharmaceuticals Inc (ELDN) News

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment...

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel...

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Form 8-K - Current report

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was...

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...